A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors

Current treatments for advanced solid tumors tend to be only palliative. Although radiotherapy is administered with a curative intent, radioresistance and dose-limiting toxicities pose limitations to treatment. Abexinostat, an oral pan-histone deacetylase inhibitor, demonstrated enhanced sensitivity...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Deutsch, Eric, Moyal, Elizabeth Cohen-Jonathan, Gregorc, Vanesa, Zucali, Paolo Andrea, Menard, Jean, Soria, Jean-Charles, Kloos, Ioana, Hsu, Jeff, Luan, Ying, Liu, Emily, Vezan, Remus, Graef, Thorsten, Rivera, Sofia
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5593555/
https://ncbi.nlm.nih.gov/pubmed/28915584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14147
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados